Electromed (NYSE:ELMD) Upgraded at StockNews.com

Electromed (NYSE:ELMD) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday.

Electromed Trading Down 2.5 %

NYSE ELMD traded down $0.76 during trading hours on Tuesday, hitting $29.20. The company’s stock had a trading volume of 186,912 shares, compared to its average volume of 98,540. Electromed has a 52 week low of $10.05 and a 52 week high of $35.56. The company has a market capitalization of $247.03 million, a PE ratio of 40.56 and a beta of 0.33. The company’s 50-day simple moving average is $31.13 and its two-hundred day simple moving average is $24.45.

Electromed (NYSE:ELMD) last posted its earnings results on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.03 by $0.13. Electromed had a net margin of 11.34% and a return on equity of 15.32%. The firm had revenue of $14.67 million for the quarter.

Insiders Place Their Bets

In other Electromed news, Director Andrew Summers sold 17,463 shares of Electromed stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67. Following the transaction, the director now owns 189,838 shares of the company’s stock, valued at $5,712,225.42. This trade represents a 8.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.00% of the company’s stock.

Hedge Funds Weigh In On Electromed

Hedge funds have recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Electromed in the 4th quarter worth approximately $59,000. Quantbot Technologies LP bought a new stake in shares of Electromed in the 4th quarter worth approximately $99,000. Barclays PLC bought a new stake in shares of Electromed in the 3rd quarter worth approximately $215,000. Bailard Inc. bought a new stake in shares of Electromed in the 4th quarter worth approximately $224,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Electromed in the 3rd quarter worth approximately $226,000. Institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.